An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Crizotinib; Docetaxel; Pemetrexed

Criteria

Inclusion Criteria:

• histologically or cytologically proven diagnosis of non-small cell lung cancer

• positive for the ALK fusion gene (test provided by a central laboratory)

• must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug

• tumors must be measurable

Exclusion Criteria:

• prior treatment with PF-02341066

• current treatment in another clinical trial